Common Residual Symptoms of Major Depressive Disorder (MDD) and an Atypical Antipsychotic for Adjunctive MDD

Overview:

This video, featuring Roger McIntyre, MD, FRCPC, highlights anxiety and anhedonia symptoms as possible residual symptoms that may be experienced by adult MDD patients with inadequate response to antidepressant therapy.

VRLR-US-00006-MC
Sponsored by: AbbVie Medical Affairs

Presenter: 

Image

Roger McIntyre, MD, FRCPC

Dr Roger S McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto. He is the chair and executive director of the Brain and Cognition Discovery Foundation in Toronto, Ontario, Canada, and the board chair of the Board of Directors of the Depression and Bipolar Support Alliance in Chicago, Illinois, USA. Additionally, he is a fellow of the American Psychiatric Association. Professor McIntyre is involved in multiple research endeavors that primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Professor McIntyre is the lead author of the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder, and he is a contributor to the Canadian Network for Mood and Anxiety Treatments guidelines for the treatment of depressive and bipolar disorders. He has published more than 900 articles and edited several textbooks on mood disorders.

References​:

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.1176/ajp.2006.163.11.1905​

2. Israel JA. The impact of residual symptoms in major depression. Pharmaceuticals (Basel). 2010;3(8):2426-2440. doi:10.3390/ph3082426 ​

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013. ​

4. Rosellini AJ, Bourgeois ML, Correa J, et al. Anxious distress in depressed outpatients: prevalence, comorbidity, and incremental validity. J Psychiatr Res. 2018;103:54-60. doi:10.1016/j.jpsychires.2018.05.006​

5. Su YA, Si T. Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder. Gen Psychiatr. 2022;35(1):e100724. doi:10.1136/gpsych-2021-100724 ​

6. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. American Psychiatric Association; 2010. ​

7. Cariprazine. Prescribing information. Allergan USA, Inc.; December 2022. ​

8. Sachs G, Yeung P, Rekeda L, et al. Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry. 2023;180(3):241-251. doi:10.1176/appi.ajp.20220504​

9. Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371-378. doi:10.4088/JCP.15m10070​

10. Fava M, Maletic V, Adams JL, et al. Efficacy of adjunctive cariprazine in patients with major depressive disorder and baseline anxiety: a post hoc analysis. Poster presented at: The Psych Congress; September 17-20, 2022; New Orleans, LA.​

11. McIntyre R, Maletic V, Massand P, et al. Effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. Poster presented at: American Society of Clinical Psychopharmacology Annual Meeting; May 30 - June 2, 2023; Miami, FL.​

​